Format

Send to

Choose Destination
Expert Rev Anticancer Ther. 2008 Jan;8(1):51-61.

Current optimal chemotherapy for advanced urothelial cancer.

Author information

1
US Oncology Research & Texas Oncology PA, 501 Medical Center Blvd, Webster, TX 77598, USA. guru.sonpavde@usoncology.com

Abstract

Conventional frontline cisplatin-based combination chemotherapy with gemcitabine and cisplatin, or traditional or dose-dense methotrexate, vinblastine, doxorubicin and cisplatin, yields high response rates but few durable remissions for advanced urothelial cancer. Salvage therapy is generally disappointing with few responses. A significant proportion of patients exhibit renal dysfunction, entailing carboplatin-based regimens that appear inferior to cisplatin-based regimens, which warrants a special focus In this population. The profusion of novel biologic agents offers the promise of improved outcomes. A multidisciplinary approach is necessary to make therapeutic advances.

PMID:
18095883
DOI:
10.1586/14737140.8.1.51
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center